Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has appointed Sanford R. Climan as a strategic advisor. The CEO and founder of Entertainment Media Ventures Inc., Climan is an active venture investor who has also served as a board member and senior advisor to an impressive array of companies. Entertainment Media Ventures is a Los Angeles-based advisory and investment company specializing in identifying opportunities in healthcare, technology, and media & entertainment industries. Climan has also served in senior management positions at Universal Studios and Metro-Goldwyn-Mayer Studios (“MGM”) and its affiliated production companies. In addition, Climan was a key member of the senior-management team at Creative Artists Agency, where he worked on teams with several Fortune 500 Companies, including Sony Corporation on its acquisition of Columbia Pictures, Matsushita Electric on its acquisition of MCA/Universal, and Credit Lyonnais on its restructuring of MGM. “Mr. Climan’s impressive background and experience in financial and healthcare industries, particularly in innovative sectors, aligns with Cybin’s mission of developing new, differentiated therapeutics for mental health conditions,” said Cybin CEO Doug Drysdale in the press release. “We are pleased to have Mr. Climan’s expertise in shaping our strategic initiatives as we continue to advance our clinical-stage programs towards key data catalysts later this year, with the goal of bringing transformative therapies to people in need of improved treatment options.”
To view the full press release, visit https://ibn.fm/dQb0c
About Cybin Inc.
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder; the company also has a research pipeline of investigational psychedelic-based compounds. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
